. Baddi Plant received OHAS Audit certification; facility approved by the regulatory authority of Uganda. An advanced facility for Stability Studies set up at Indrad Plant. Entered into the therapeutic area of Gynaecology.
Commenced commercial operations of Laboratories Torrent S.A. De C.V., Mexico. Started construction of Dahej manufacturing facility. Commissioned a subsidiary in United Kingdom and Romania. Torrent Research Center develops Long Acting Injectables technology. Foray into oncology segment.
New manufacturing unit at Baddi, Himachal Pradesh, set up to cater to domestic formulations market. Torrent Pharma signed an agreement with Novo Nordisk India to establish a new, dedicated formulation and packaging facility for Insulin, exclusively for Novo Nordisk. Acquired Heumann Pharma GmbH & Co Generica KG, a Pfizer group company, in Germany. Two new marketing divisions- AXON and NEURON set up to cater to neuropsychiatry segment. Entered into a research collaboration with AstraZeneca for developing novel anti-hypertensive drug. Torrent Pharma's QC department at Chhatral manufacturing plant accredited with ISO/IEC- 17025 by NABL.
Discovered and patented AGE (Advanced Glycosylation End-products) molecule. Torrent Pharma's Indrad Plant receives ISO and OHSAS. Torrent's R&D Centre received ISO/IEC for its facilities by National Accreditation Board for Testing and Calibration Laboratories (NABL). Addition of a new marketing division, MIND. Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System and Multiparticulate / Matrix Based SR / Modified Release Formulations developed indigenously by Torrent Research Center (2002). Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities. Brazilian Sanitary Surveillance Agency accredited Torrent's R&D Centre with ANVISA, authorizing it to conduct Bioequivalance Studies.
. Annovera (ethinyl estradiol and segesterone acetate) is an estrogen and progestin vaginal contraceptive. Mulpleta (lusutrombopag) is a once-daily, orally administered, thrombopoietin (TPO) receptor agonist for the. Orilissa (elagolix) is an orally administered gonadotropin-releasing hormone (GnRH) antagonist for the.
Tibsovo (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor for the treatment of patients with. Krintafel (tafenoquine) is an 8-aminoquinoline derivative antimalarial for the radical cure (prevention of. Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) is a once daily, single-tablet.
To Start receiving timely alerts please follow the below steps:. Click on the Menu icon of the browser, it opens up a list of options. Click on the “Options ”, it opens up the settings page,. Here click on the “Privacy & Security” options listed on the left hand side of the page. Scroll down the page to the “Permission” section.
Here click on the “Settings” tab of the Notification option. A pop up will open with all listed sites, select the option “ALLOW“, for the respective site under the status head to allow the notification. Once the changes is done, click on the “Save Changes” option to save the changes. Ahmedabad, Oct 6 (UNI) Ahmedabad-based pharma major, the Rs 1,033 crores Torrent Pharma has launched three specialty divisions - Omega, Sensa and Alfa.
The new divisions will cater exclusively to the fast growing niche therapeutic areas of Cardio-Diabeta, Central Nervous System and Gastro segments respectively. 'The launch of these exclusive divisions will not only strengthen the company's presence in these high growth potential segments but will also substantially improve its topline,' according to a release issued here today.
Division Product Math
Omega, the new cardio-diabeta (C&D) division, will exclusively focus on the cardio-metabolic diseases, with special focus on diabetes and nephrology. Torrent, with sales of Rs 180 crore, currently has a 4.8 per cent share in the Rs 3,750 crore C&D market. Omega will complement Torrent's existing C&D divisions, Azuca, Delta and Psycan and will help the company increase its market share considerably. The new CNS division, Sensa, will focus exclusively on the ailments inflicting the geriatric population. This includes Parkinsons', Alzheimers's and depression that are some of the most prevalent ailments in this segment.
Monte Vista Division Of Wildlife
The CNS market in India is estimated to be around Rs 1,200 crore of which Torrent has a 5.5 per cent share. It has been growing at almost 2.5 times faster than the industry, clocking 50 per cent growth as per ORG MAT, July this year. With 60 new field personnel, Sensa will reach out to more specialists in this niche population segment. The third new division, Alfa is in the mass products segment and will focus on gastro, ortho, and anti-infectives segments. The gastro-intestinal market is worth around Rs 3,000 crore and is growing at 19 per cent. Alfa will join the existing divisions, Prima and Vista, in this category and is expected to substantially push the revenues from this basket from current Rs 262 crores (ORG July MAT 2006). The company plans to deploy around 200 new field personnel in this new division to drive growth.
Torrent Pharma has since long followed a divisionalisation and segmentation strategy to improve its doctor coverage and generate incremental business through the prescription generation route. The release said quoting Ruchir Modi, Head-Strategic Marketing: 'Divisionalisation will help us launch molecules with greater regularity. This will ensure better doctor coverage, more prescriptions and therefore, higher sales revenues.'
' The company has rapidly built up a good CNS and C&D portfolio in the last two years on the basis of their growth potential. Today, Torrent Pharma has eight marketing divisions of which four are dedicated to the CNS segment; the only pharma company in the industry to have so. This is a reflection of the company's focus on these high-potential areas. Its existing divisions, Mind, Neuron and Axon deal primarily with Anti-Epilepsy, anti-Depressants, anti-Psychotics, Anti-Alzheimer's, Neurotonics and Parkinson's. Memory map licence keygen idm.
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you.
If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time.
Torrent Pharma, a Rs.5,800 crore Ahmedabad based pharma giant, has posted strong topline growth during the first quarter ended June 2018, but its bottomline hit by higher provision for interest cost a. Torrent Pharma has made “substantial progress” with the integration of the acquired Unichem business, turning around key brands and building. AstraZeneca's plan to brand 18 generic products and market them in 9 countries Companies responding to inquiries from Sens. Elizabeth Warren, D-Mass., and Tina Smith, D-Minn., did not indicate they are planning to. Denmark’s LEO Pharma has sold a product portfolio of 10 products to Swedish firm Karo Pharma for 260 SummaryTorrent Pharmaceuticals Ltd Torrent manufactures and markets branded and unbranded generic pharmaceuticals. It provides products in cardiovascular, central nervous system, gastrointestinal, dia.
SummaryTorrent Pharmaceuticals Ltd Torrent manufactures and markets branded and unbranded generic pharmaceuticals. It provides products in cardiovascular, central nervous system, gastrointestinal, dia. Twenty-two medtech products were removed by the US Trade Representative from the list of products manufactured in China that -More- Matching PubMed Articles. In recent years, chimeric antigen receptor (CAR) modified T cells have been used as a treatment for haematological malignancies in several phase I and II trials and with Kymriah of Novartis and Yescar. Gluten-free (GF) products are consumed both by individuals with celiac disease and by an increasing number of people with no specific medical needs. Although the technological quality of GF products h.
Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence. Purpose Prepare a list of noun phrases able to characterize the writing performance of schoolchildren according to school year.
Methods A list of 25 noun phrases intended for dictation was prepared an. Many oxidation-reduction (redox) enzymes, particularly oxygenases, have roles in reactions that make and break C-C bonds. The list includes cytochrome P450 and other heme-based monooxygenases, heme-ba. Search Whole site using Google. The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment.
The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters here:. All rights reserved. All other trademarks recognized. Copyright © 1997-2018 BioPortfolio Limited. Site developed.